TSH modulation in advanced differentiated thyroid cancer: a continuous walk on the tightrope between prognostic stratification, adverse events, and levothyroxine bioavailability

被引:1
|
作者
Marotta, Vincenzo [1 ]
Botti, Gerardo [2 ]
Ionna, Franco [3 ]
Pezzullo, Luciano [1 ]
机构
[1] Ist Nazl Tumori IRCCS G Pascale Fdn, Serv Oncol Thyroid Surg, Via M Semmola 53, I-80131 Naples, Italy
[2] Ist Nazl Tumori IRCCS G Pascale Fdn, Serv Anat Pathol & Cytopathol, Naples, Italy
[3] Ist Nazl Tumori IRCCS G Pascale Fdn, Serv Maxillofacial & ENT Oncol Surg, Naples, Italy
来源
MINERVA ENDOCRINOLOGY | 2022年 / 47卷 / 01期
关键词
THYROTROPIN SUPPRESSION; CARCINOMA; OUTCOMES; THERAPY; ASSOCIATION; MANAGEMENT; RECURRENCE; MORTALITY; PAPILLARY;
D O I
10.23736/S2724-6507.20.03334-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:99 / 102
页数:4
相关论文
共 1 条
  • [1] MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH CABOZANTINIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA, HEPATOCELLULAR CARCINOMA, OR RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
    Lee-Ramos, Steven
    Seery, Virginia
    Andresen, Diane
    Hall, Tasha
    Berry, Nicholas
    Martone, Brenda
    ONCOLOGY NURSING FORUM, 2024, 51 (02)